A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol
Information source: AOP Orphan Pharmaceuticals AG
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy Volunteers; Pharmacokinetics/Dynamics Study
Intervention: AOP200704 (Drug); Esmolol hydrochloride, infusion (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: AOP Orphan Pharmaceuticals AG Official(s) and/or principal investigator(s): AOP Study Principal Investigator, Principal Investigator, Affiliation: AOP Contract Clinical Research Facility
Summary
Pharmacokinetics, pharmacodynamics and tolerability of AOP200704 infusion is compared to
that of Esmolol by measurement of plasma concentrations of AOP200704, esmolol and their
metabolites, by assessing the effect of both drugs on dobutamine-induced tachycardia, and by
monitoring vital signs, ECG and adverse events.
Clinical Details
Official title: A Prospective, Randomized, Double Blinded, Crossover, Two-treatment, Two-sequence, Short Term Pharmacokinetic, Pharmacodynamic and Tolerability, Single Centre Study to Compare AOP200704 vs. Esmolol in Healthy Subjects.
Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Pharmacokinetics/dynamics
Secondary outcome: Local tolerability
Detailed description:
16 healthy volunteers of both sexes, age 18 to 45 years, will be enrolled. The mean dose
necessary to suppress the Dobutamine induced heart rate increase of at least 30 bpm above
baseline rate (maximum heart rate app. 110 bpm) by at least 20 bpm will be calculated for
AOP200704 and Esmolol and the dose/efficacy relation of both agents to each other will be
calculated for the steady state condition. For both drugs the time to reach a decrease of 10
bpm, 20 bpm and the maximum effect will be calculated. In addition the mean time to increase
in 10 and 20 bpm and the time to reach maximum heart rate (increase of 30 bpm above baseline
or more) after termination of infusion will also be assessed for both drugs. Blood pressure
values will be compared for all above mentioned time points where heart rate is assessed for
pharmacodynamics. The study will consist of a screening, cross-over 1, cross-over 2 and
end-of-study visit.
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male and female human subjects, age 18-45 years
- Body weight of at least 50 kg, maximum of 90 kg. Body-mass index 18. 5 to 30. 0 kg/m2
- Caucasians
- Subjects without clinically relevant abnormalities
- Subjects agreeing to not using any prescription and over the counter medications
including vitamins and minerals for 7 days prior to study and during the course of
the study
- No drug or alcohol abuse
- Non-smokers, ex smokers and mild smokers
Exclusion Criteria:
- Subjects with history or presence of clinically relevant cardiovascular, renal,
hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological,
gastrointestinal, endocrine, immunological, psychiatric or skin diseases.
- Subjects with bradycardia (heart rate below 50 bpm), tachycardia (heart rate above
100 bpm), hypotension (systolic blood pressure below 100 mmHg, and/or diastolic blood
pressure below 70 mm Hg) at screening, clinically relevant or history of clinically
relevant arrhythmias
- Subjects with clinically relevant cardiac supraventricular or ventricular
arrhythmias.
- Subjects with atrioventricular block of grade II and III, sick sinus syndrome,
sinoatrial block or congestive heart failure
- Participation in a clinical drug study or bioequivalence study 60 days prior to
present study.
- History of malignancy or other serious diseases.
- Any contraindication to blood sampling.
- History of i. v. drug abuse.
- Subjects with positive HIV tests, HBsAg or Hepatitis C tests or other acute, subacute
or chronic infectious disease.
Locations and Contacts
AOP contract research facility, Pilsen 32300, Czech Republic
Additional Information
Sponsor
Starting date: March 2011
Last updated: July 18, 2012
|